Phase 2Completed
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions
- Sponsor
- Vogenx, Inc. (Industry)
- Enrollment
- 15 enrolled
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin; Placebo
- Ages
- adults, older adults
- Registry
- NCT05721729
Full record on ClinicalTrials.gov
From the registry
This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.
Primary outcomes
- Glucose Nadir
History
Results posted
Last registry update
Study completion
Primary completion
Started
Registered